Edition:
United Kingdom

Idera Pharmaceuticals Inc (IDRA.OQ)

IDRA.OQ on NASDAQ Stock Exchange Capital Market

2.55USD
8:59pm GMT
Change (% chg)

$0.14 (+6.03%)
Prev Close
$2.40
Open
$2.37
Day's High
$2.55
Day's Low
$2.37
Volume
332,539
Avg. Vol
482,937
52-wk High
$2.87
52-wk Low
$1.30

Latest Key Developments (Source: Significant Developments)

Idera Pharmaceuticals Provides 2018 Update And Outlook
Friday, 5 Jan 2018 

Jan 5 (Reuters) - Idera Pharmaceuticals Inc ::IDERA PHARMACEUTICALS PROVIDES 2018 UPDATE AND OUTLOOK.IDERA PHARMACEUTICALS - ANTICIPATES CURRENT CASH POSITION CAPABLE OF FUNDING OPERATIONS INTO Q2 2019.  Full Article

U.S. FDA Grants Fast Track Designation For Idera Pharmaceuticals’ IMO-2125 In Combination With Ipilimumab
Wednesday, 29 Nov 2017 

Nov 29 (Reuters) - Idera Pharmaceuticals Inc ::U.S. FDA GRANTS FAST TRACK DESIGNATION FOR IDERA PHARMACEUTICALS’ IMO-2125 IN COMBINATION WITH IPILIMUMAB FOR TREATMENT OF PD-1 REFRACTORY METASTATIC MELANOMA.  Full Article

Idera Pharmaceuticals reports Q3 loss per share $0.10
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Idera Pharmaceuticals Inc :Idera Pharmaceuticals reports third quarter 2017 financial results and provides corporate update.Q3 loss per share $0.10.Q3 earnings per share view $-0.12 -- Thomson Reuters I/B/E/S.Idera Pharmaceuticals Inc - ‍ as of September 30, 2017, cash, cash equivalents and investments totaled $65.3 million​.Idera Pharmaceuticals Inc - ‍currently anticipate cash position capable of funding co's operations into Q2 of 2019​.  Full Article

Idera Pharma announces pricing of public offering of common stock
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Idera Pharmaceuticals Inc :Idera Pharmaceuticals announces pricing of public offering of common stock.Says public offering of 33.3 million common shares priced at $1.50 per share.  Full Article

Idera Pharmaceuticals announces proposed public offering of common stock
Tuesday, 24 Oct 2017 

Oct 24 (Reuters) - Idera Pharmaceuticals Inc :Idera Pharmaceuticals announces proposed public offering of common stock.Idera Pharmaceuticals Inc - ‍intends to offer and sell up to $60 million of shares of its common stock in an underwritten public offering​.Idera - intends to use net proceeds from offering, together with existing cash to advance development of IMO-2125 in its immuno-oncology program​.  Full Article

Idera Pharmaceuticals Q3 loss per share $0.10
Friday, 28 Oct 2016 

Idera Pharmaceuticals Inc : Idera Pharmaceuticals reports third quarter 2016 financial results . Q3 loss per share $0.10 . Q3 earnings per share view $-0.12 -- Thomson Reuters I/B/E/S . Q3 revenue $300,000 .Q3 revenue view $117,000 -- Thomson Reuters I/B/E/S.  Full Article

Baker Bros. Advisors LP reports 7.2 pct stake in Idera Pharmaceuticals - SEC filing
Tuesday, 11 Oct 2016 

Baker Bros. Advisors LP:Baker Bros. Advisors LP reports 7.2 percent stake in Idera Pharmaceuticals Inc as of Oct. 7 - sec filing.  Full Article

Idera Pharmaceuticals says public offering of 25 mln common shares priced at $2.00 per share
Friday, 7 Oct 2016 

Idera Pharmaceuticals Inc : Idera Pharmaceuticals announces pricing of public offering of common stock .Says public offering of 25.0 million common shares priced at $2.00per share.  Full Article

Idera Pharma says announces proposed public offering of common stock
Wednesday, 5 Oct 2016 

Idera Pharmaceuticals : Idera pharmaceuticals inc says intends to offer and sell up to $50,000,000 of shares of its common stock in an underwritten public offering . Idera pharmaceuticals announces proposed public offering of common stock . Idera pharmaceuticals inc says intends to offer and sell up to $50 million of shares of its common stock in an underwritten public offering .Intends to use net proceeds from offering to advance clinical development of certain of its programs.  Full Article

Idera Pharmaceuticals Q2 loss per share $0.11
Tuesday, 2 Aug 2016 

Idera Pharmaceuticals Inc : Q2 loss per share $0.11 . Q2 revenue $300,000 . Idera Pharmaceuticals reports second quarter 2016 financial results and provides corporate update . Q2 earnings per share view $-0.11 -- Thomson Reuters I/B/E/S .Q2 revenue view $142,000 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Idera Pharmaceuticals Provides 2018 Update And Outlook

* IDERA PHARMACEUTICALS - ANTICIPATES CURRENT CASH POSITION CAPABLE OF FUNDING OPERATIONS INTO Q2 2019 Source text for Eikon: Further company coverage: